VBL Presents New Data on the Potential of its Novel VB-600 Platform for Nonalcoholic Steatohepatitis (NASH) and Rheumatoid Arthritis (RA) Biotech Investing
Spero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR720 Biotech Investing
Eyenovia Announces Confirmatory Results from Second MicroStat Phase III Registration Study for Mydriasis Biotech Investing
